• Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 112

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

Book Club – Trip Sitting

Book Club! Built To Burn: Tales of the Desert Carnies of Burning Man

Late-Stage Psychedelic Trials: A brief review of the two most mature...

Bright Minds Biosciences Announces Receipt of Nasdaq Notification Letter Regarding Minimum...

Doing Things Differently: Beyond Business as Usual in the Psychedelics Space

Adelaide Wilcox King: The Psychedelic Industry as a Catalyst for Reimagining...

Julia Mande: Consider the Conditions: Growing a Psychedelic Ecosystem

BetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary...

PT384 – Vital Psychedelic Conversations

Adapting to the Squeeze: Spending Trends, Slimming Pipelines, M&A and Partnerships...

Psychedelic Investor Pulse Survey – Q4 2022

MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2023

1...111112113...299Page 112 of 299

EDITOR PICKS

Psychedelic Futures – Nowak Society featuring Joe Moore

Q2 2025: Oregon Psilocybin Services Update

Solidarity Fridays – Joe Moore and Kyle Buller

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    ©